Board of Directors
Dr. Seth Rudnick has extensive expertise in oncology, drug discovery and development, and healthcare investments. He is recently retired from Canaan Partners, where he built the global venture capital firm's capability in biopharmaceutical investing. Prior to joining Canaan, he was the chief executive officer and chairman of CytoTherapeutics, a developer of cell therapies to combat chronic diseases. He also helped start and led the development of Ortho Biotech, a division of Johnson & Johnson. Earlier in his career, Dr. Rudnick worked at Shering-Plough and directed pharmaceutical development efforts at Biogen.
Dr. Rudnick was a Yale Fellow in medical oncology where he was also a Robert Wood Johnson Scholar. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. He is a Clinical Professor of Medicine at the University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. He also currently serves as the chariman of Liquidia Technologies, Drug innovation Ventures at Emory (DRIVE) and Meryx, and serves on the boards of Vaxinnate, POZEN and Square 1 Financial.
Fred Eshelman is the founder and principle of Eshelman Ventures LLC, investing in a variety of companies, primarily health care. Prior to that, he was the founding chairman of Furiex Pharmaceuticals (FURX, NASDAQ); the company was sold to Forest Labs/Actavis in July, 2014.
Previously, he founded and served as CEO and Executive Chairman for Pharmaceutical Product Development, Inc. (PPDI, NASDAQ) until sale of the company to private equity interests (Carlyle, Hellman & Friedman). His career has also included positions as Senior Vice President, Development and board member at Glaxo Inc., as well as various management positions at Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. He serves on a number of of industry boards. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and the board of the NC Biotechnology Center.
He is active in higher education, serving on the Board of Governors for the UNC System (chaired Audit Committee) and as an adjunct professor at the UNC School of Pharmacy, where he chairs the Board of Visitors. One of the top pharmacy programs in the US, in May 2008 the school was named the Eshelman School of Pharmacy, in recognition of his many contributions to the school and profession.
He has received many awards, including the Davie and Outstanding Service awards from UNC-Chapel Hill and outstanding alumnus awards from UNC and University of Cincinnati schools of pharmacy. He has also received the Ernst & Young Entrepreneur of the Year and the NC Entrepreneur Hall of Fame Award.
Dr. Eshelman holds a BSc pharmacy from UNC-CH, a doctor of pharmacy from the University of Cincinnati and completed a hospital residency at Cincinnati General Hospital. He completed the Owner/President/Manager program at Harvard Business School.
Peter Kolchinsky is a founder, Managing Director, and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics and a number of private companies. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry. He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academies of Sciences. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.
Glenn P. Muir has extensive experience in financial management, having guided Hologic from its early days with less than $10 million in revenue to its current position as one of the largest life science companies with annual revenues of over $2 billion. He was Hologic’s Chief Financial Officer from 1992 to May 2014 and Executive Vice President since 2000 with a broad range of financial and operating responsibilities, including the oversight of the company’s strategic initiatives. Mr. Muir was at the helm for Hologic’s IPO in 1990. Currently on the Board of Repligen Corporation and the Audit Committee Chair at ReWalk Robotics and RainDance Technologies, his Board of Director experience also includes Hologic, Inc. from 2001 to 2013 and Vivid Technologies, Inc. from 1996 until the company was sold to EG&G in 1999. He was named one of America’s Best CFOs by Institutional Investor in 2009 and CFO of the year by Boston Business Journal in 2011. Mr. Muir holds a B.B.A. with a major in accounting from the University of Massachusetts in Amherst, an M.B.A. from Harvard Business School, and an M. Sc. in taxation from Bentley College Graduate School of Business. Mr. Muir is also a member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants.
Tyrell Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments. Prior to joining AstraZeneca, Tyrell was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Tyrell earned his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and his M.B.A. from the New York University Stern School of Business. Tyrell also serves on the Board of Directors for Armaron Bio Ltd and Corvidia Therapeutics and as a Board observer for several private companies.
Christy L. Shaffer, PhD, has over 20 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals. As President and CEO, Dr. Shaffer grew the company from 20 scientists to nearly 250 employees with revenues of over $100 million. Dr. Shaffer retired from Inspire in March, 2010 and the company was acquired by Merck in 2011. Dr. Shaffer then began her role as Venture Partner and Managing Director of Hatteras Discovery, part of Hatteras Venture Partners, a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine.
Dr. Shaffer played an integral role in the Chancellor's Innovation Circle to enhance entrepreneurship and innovation across the UNC-Chapel Hill campus (2010 - 2012). She has served on numerous boards including the Council for Entrepreneurial Development, the NC Biotechnology Center, the Biotechnology Institute, BIO, PhRMA and Clinipace Worldwide. She currently serves on the Board of Trustees for the Cystic Fibrosis Foundation and is the current Foundation Board Chair for the NC School of Science and Mathematics. Dr. Shaffer is a receptor pharmacologist by training, earning her PhD in Pharmacology from the University of Tennessee. Her post-doctoral training was completed at The Chicago Medical School and the University of North Carolina at Chapel Hill.
Tim Sullivan is a Partner at Aju IB Investment Co., Ltd., a venture capital firm with operations in Seoul Korea and the U.S. Mr. Sullivan is a board member of Molecular Templates and board observer at several other private biotechnology companies. Prior to his role at Aju IB Investment, Mr. Sullivan was Managing Director in charge of Life Sciences Banking at RBS Citizens. Earlier, Mr. Sullivan served as EVP and Head of Corporate Development at Cornerstone Pharmaceuticals, and worked in healthcare investment banking at Jefferies & Co. as well as Bear Stearns & Co. Inc. Mr. Sullivan holds an MBA from Columbia Business School and a BA in Biology from Harvard University.
Dr. Velleca joined G1 as chief executive officer in 2014. Previously, he was at CGI Pharmaceuticals, where he guided the company from its inception through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. After CGI was acquired by Gilead Sciences, Dr. Velleca served as a senior advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Dr. Velleca earned a BS from Yale University and an MD and PhD from Washington University in St. Louis. He has served on the board of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company that was acquired by Takeda in 2011. He most recently served as executive vice president at The Leukemia & Lymphoma Society.